Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic, off-the-shelf natural killer cell therapies. Natural killer cells are immune cells that can destroy diseased cells, and Artiva manufactures them from donor cells at scale so they can be given to patients without individual customization.

The company's lead candidate, AlloNK, is being studied in combination with monoclonal antibodies that deplete B cells, with a focus on autoimmune diseases such as lupus nephritis and rheumatoid arthritis, where resetting the B cell population may help control disease. Artiva has also explored its platform in oncology.

Artiva is headquartered in San Diego, California, and completed its initial public offering on Nasdaq in 2024.